Reinstating aberrant mTORC1 activity in huntington's disease mice improves disease phenotypes

Neuron

Volumn 85, Issue 2, 2015, Pages 303-315

  Lee, John H ^a   Tecedor, Luis ^b   Chen, Yong Hong ^b   Monteys, Alex Mas ^b   Sowada, Matthew J ^b   Thompson, LeslieM ^c   Davidson, Beverly L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAS HOMOLOG ENRICHED IN THE STRIATUM PROTEIN; RAS PROTEIN; RHEB PROTEIN; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; RASD2 PROTEIN, MOUSE; RHEB PROTEIN, MOUSE; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN MITOCHONDRION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; HOMEOSTASIS; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; ANIMAL; ATROPHY; DISEASE MODEL; GENETICS; HUMAN; LIPOGENESIS; METABOLISM; NEOSTRIATUM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATROPHY; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEINS; HUMANS; HUNTINGTON DISEASE; LIPOGENESIS; MICE; MONOMERIC GTP-BINDING PROTEINS; MULTIPROTEIN COMPLEXES; NEOSTRIATUM; NEUROPEPTIDES; PHENOTYPE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84921411838     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.12.019     Document Type: Article

References (69)

1. Baiamonte B.A., Lee F.A., Brewer S.T., Spano D., LaHoste G.J. Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease. PLoS ONE 2013, 8:e53606.
2. Bhattacharya A., Kaphzan H., Alvarez-Dieppa A.C., Murphy J.P., Pierre P., Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76:325-337.
3. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA 2000, 97:6809-6814.
4. Cheng Y., Peng Q., Hou Z., Aggarwal M., Zhang J., Mori S., Ross C.A., Duan W. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 2011, 56:1027-1034.
5. Choi B.R., Bang S., Chen Y., Cheah J.H., Kim S.F. PKA modulates iron trafficking in the striatum via small GTPase, Rhes. Neuroscience 2013, 253:214-220.
6. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
7. Cunningham J.T., Rodgers J.T., Arlow D.H., Vazquez F., Mootha V.K., Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
8. Fox J.H., Connor T., Chopra V., Dorsey K., Kama J.A., Bleckmann D., Betschart C., Hoyer D., Frentzel S., Difiglia M., et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails toreduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol. Neurodegener. 2010, 5:26.
9. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 2005, 102:5820-5825.
10. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
11. Humbert S., Bryson E.A., Cordelières F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2002, 2:831-837.
12. Jeong H., Then F., Melia T.J., Mazzulli J.R., Cui L., Savas J.N., Voisine C., Paganetti P., Tanese N., Hart A.C., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
13. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 2012, 21:5280-5293.
14. Jiang M., Peng Q., Liu X., Jin J., Hou Z., Zhang J., Mori S., Ross C.A., Ye K., Duan W. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum. Mol. Genet. 2013, 22:2462-2470.
15. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J.Neurochem. 2006, 97:737-746.
16. Karasinska J.M., Hayden M.R. Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 2011, 7:561-572.
17. Kim S.R., Kareva T., Yarygina O., Kholodilov N., Burke R.E. AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol. Ther. 2012, 20:275-286.
18. Kreiner G., Bierhoff H., Armentano M., Rodriguez-Parkitna J., Sowodniok K., Naranjo J.R., Bonfanti L., Liss B., Schütz G., Grummt I., Parlato R. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ. 2013, 20:1455-1464.
19. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
20. Lee J.H., Sowada M.J., Boudreau R.L., Aerts A.M., Thedens D.R., Nopoulos P., Davidson B.L. Rhes suppression enhances disease phenotypes in Huntington's disease mice. J.Huntingtons Dis. 2014, 3:65-71.
21. Li H., Li S.H., Yu Z.X., Shelbourne P., Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J.Neurosci. 2001, 21:8473-8481.
22. Lu B., Palacino J. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 2013, 27:1820-1829.
23. Mason R.P., Casu M., Butler N., Breda C., Campesan S., Clapp J., Green E.W., Dhulkhed D., Kyriacou C.P., Giorgini F. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat. Genet. 2013, 45:1249-1254.
24. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 2008, 105:5868-5873.
25. Mealer R.G., Subramaniam S., Snyder S.H. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. J.Neurosci. 2013, 33:4206-4210.
26. Mealer R.G., Murray A.J., Shahani N., Subramaniam S., Snyder S.H. Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. J.Biol. Chem. 2014, 289:3547-3554.
27. Michel R.P., Cruz-Orive L.M. Application of the Cavalieri principle and vertical sections method to lung: estimation of volume and pleural surface area. J.Microsc. 1988, 150:117-136.
28. Mielcarek M., Landles C., Weiss A., Bradaia A., Seredenina T., Inuabasi L., Osborne G.F., Wadel K., Touller C., Butler R., et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 2013, 11:e1001717.
29. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
30. Narita M., Young A.R., Arakawa S., Samarajiwa S.A., Nakashima T., Yoshida S., Hong S., Berry L.S., Reichelt S., Ferreira M., et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 2011, 332:966-970.
31. O'Rourke J.G., Gareau J.R., Ochaba J., Song W., Raskó T., Reverter D., Lee J., Monteys A.M., Pallos J., Mee L., et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep. 2013, 4:362-375.
32. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., He Z. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
33. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., Guertin D.A., Madden K.L., Carpenter A.E., Finck B.N., Sabatini D.M. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146:408-420.
34. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.L., Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8:224-236.
35. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
36. Roscic A., Baldo B., Crochemore C., Marcellin D., Paganetti P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J.Neurochem. 2011, 119:398-407.
37. Saxena S., Roselli F., Singh K., Leptien K., Julien J.P., Gros-Louis F., Caroni P. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 2013, 80:80-96.
38. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
39. Schulte J., Sepp K.J., Wu C., Hong P., Littleton J.T. High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS ONE 2011, 6:e23841.
40. Seredenina T., Gokce O., Luthi-Carter R. Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS ONE 2011, 6:e22231.
41. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
42. She P., Zhang Z., Marchionini D., Diaz W.C., Jetton T.J., Kimball S.R., Vary T.C., Lang C.H., Lynch C.J. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E49-E61.
43. Shoji-Kawata S., Sumpter R., Leveno M., Campbell G.R., Zou Z., Kinch L., Wilkins A.D., Sun Q., Pallauf K., MacDuff D., et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013, 494:201-206.
44. Simmons D.A., Belichenko N.P., Yang T., Condon C., Monbureau M., Shamloo M., Jing D., Massa S.M., Longo F.M. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J.Neurosci. 2013, 33:18712-18727.
45. Spano D., Branchi I., Rosica A., Pirro M.T., Riccio A., Mithbaokar P., Affuso A., Arra C., Campolongo P., Terracciano D., et al. Rhes is involved in striatal function. Mol. Cell. Biol. 2004, 24:5788-5796.
46. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jäger S., Handschin C., Zheng K., Lin J., Yang W., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
47. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
48. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
49. Subramaniam S., Napolitano F., Mealer R.G., Kim S., Errico F., Barrow R., Shahani N., Tyagi R., Snyder S.H., Usiello A. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat. Neurosci. 2012, 15:191-193.
50. Sun F., Park K.K., Belin S., Wang D., Lu T., Chen G., Zhang K., Yeung C., Feng G., Yankner B.A., He Z. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature 2011, 480:372-375.
51. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., Borowsky B., Landwehrmeyer B., Frost C., Johnson H., et al. Predictors of phenotypic progression and disease onset in premanifest andearly-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12:637-649.
52. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
53. Thompson L.M., Aiken C.T., Kaltenbach L.S., Agrawal N., Illes K., Khoshnan A., Martinez-Vincente M., Arrasate M., O'Rourke J.G., Khashwji H., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J.Cell Biol. 2009, 187:1083-1099.
54. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J.Biol. Chem. 2009, 284:8023-8032.
55. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V.C., Sharp A.H., Persichetti F., Cattaneo E., MacDonald M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 2000, 9:2799-2809.
56. Troca-Marín J.A., Alves-Sampaio A., Montesinos M.L. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. J.Neurosci. 2011, 31:9445-9455.
57. Tsai P.T., Hull C., Chu Y., Greene-Colozzi E., Sadowski A.R., Leech J.M., Steinberg J., Crawley J.N., Regehr W.G., Sahin M. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012, 488:647-651.
58. Tsunemi T., La Spada A.R. PGC-1alpha at the intersection of bioenergetics regulation and neuron function: From Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 2011, 97:142-151.
59. Tsunemi T., Ashe T.D., Morrison B.E., Soriano K.R., Au J., Roque R.A., Lazarowski E.R., Damian V.A., Masliah E., La Spada A.R. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 2012, 4:142ra197.
60. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
61. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J.Neurosci. 2005, 25:9932-9939.
62. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
63. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J.Neurosci. 2010, 30:14708-14718.
64. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
65. Yamamoto A., Cremona M.L., Rothman J.E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J.Cell Biol. 2006, 172:719-731.
66. Yu L., McPhee C.K., Zheng L., Mardones G.A., Rong Y., Peng J., Mi N., Zhao Y., Liu Z., Wan F., et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
67. Zhou X., Lin D.S., Zheng F., Sutton M.A., Wang H. Intracellular calcium and calmodulin link brain-derived neurotrophic factor to p70S6 kinase phosphorylation and dendritic protein synthesis. J.Neurosci. Res. 2010, 88:1420-1432.
68. Zou J., Zhou L., Du X.X., Ji Y., Xu J., Tian J., Jiang W., Zou Y., Yu S., Gan L., et al. Rheb1 is required for mTORC1 and myelination in postnatal brain development. Dev. Cell 2011, 20:97-108.
69. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.